Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

ABSTRACT:

Background

Inhibition of the anaplastic lymphoma kinase (alk) oncogenic driver in advanced non-small-cell lung carcinoma (nsclc) improves survival. In 2015, Canadian thoracic oncology specialists published a consensus guideline about the identification and treatment of ALK-positive patients, recommending use of the alk inhibitor crizotinib in the first line. New scientific literature warrants a consensus update.

Methods

Clinical trials of alk inhibitor were reviewed to assess benefits, risks, and implications relative to current Canadian guidance in patients with ALK-positive nsclc.

Results

Randomized phase iii trials have demonstrated clinical benefit for single-agent alectinib and ceritinib used in treatment-naïve patients and as second-line therapy af

SUBMITTER: Melosky B 

PROVIDER: S-EPMC6209554 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature